Dhital Rashmi, Poudel Dilli Ram, Tachamo Niranjan, Gyawali Bishal, Basnet Sijan, Shrestha Pragya, Karmacharya Paras
Department of Internal Medicine, Reading Health System, Pennsylvania.
Department of Internal Medicine, Reading Health System, Pennsylvania.
J Stroke Cerebrovasc Dis. 2017 Dec;26(12):2926-2934. doi: 10.1016/j.jstrokecerebrovasdis.2017.07.015. Epub 2017 Aug 15.
Stroke is the fifth leading cause of mortality in the United States and a leading cause of disability. A complex relationship between thyroid hormone levels and severity of, and outcome after, stroke has been described.
Our objective is to identify the association between baseline thyroid function profile and outcome after acute ischemic stroke.
Studies looking at the association between thyroid function and functional stroke outcomes were identified from available electronic databases from inception to December 16, 2016. Study-specific risk ratios were extracted and combined with a random effects model meta-analysis.
In the analysis of 12 studies with 5218 patients, we found that subclinical hypothyroidism was associated with better modified Rankin scale scores at 1 and 3 months (odds ratio [OR] 2.58, 95% confidence interval [CI] 1.13-5.91, P = .03 and OR 2.28, 95% CI 1.13-3.91, P = .003, respectively) compared with the euthyroid cases. Likewise, patients with higher initial thyrotropin-releasing hormone (TSH) and fT3 or T3 levels had favorable outcomes at discharge (mean differences of TSH .12 [95% CI .03-.22, P = .009] and of fT3 .36 (CI .20-.53, P < .0001]) and at 3 months (mean differences of TSH .25 [95% CI .03-.47, P = .03] and of T3 8.60 [CI 4.58-12.61, P < .0001]).
Elevated initial TSH (clinical or subclinical hypothyroidism) may correspond to better functional outcomes, whereas low initial T3/fT3 might correlate with worse outcomes in acute ischemic stroke among clinically euthyroid patients. This complex relation merits further well-designed investigations. Whether correcting thyroid profile with hormone supplementation or antagonism may lead to improved outcomes will require large, prospective, interventional studies.
中风是美国第五大死亡原因,也是导致残疾的主要原因。甲状腺激素水平与中风的严重程度及预后之间存在复杂的关系。
我们的目标是确定急性缺血性中风后基线甲状腺功能状况与预后之间的关联。
从起始至2016年12月16日的可用电子数据库中识别出研究甲状腺功能与中风功能结局之间关联的研究。提取特定研究的风险比,并结合随机效应模型进行荟萃分析。
在对12项研究中的5218例患者进行分析时,我们发现,与甲状腺功能正常的病例相比,亚临床甲状腺功能减退与1个月和3个月时改良Rankin量表评分更好相关(优势比[OR]分别为2.58,95%置信区间[CI]为1.13 - 5.91,P = 0.03;OR为2.28,95% CI为1.13 - 3.91,P = 0.003)。同样,初始促甲状腺激素释放激素(TSH)及游离三碘甲状腺原氨酸(fT3)或三碘甲状腺原氨酸(T3)水平较高的患者出院时(TSH的平均差异为0.12 [95% CI为0.03 - 0.22,P = 0.009],fT3的平均差异为0.36 [CI为0.20 - 0.53,P < 0.0001])及3个月时(TSH的平均差异为0.25 [95% CI为0.03 - 0.47,P = 0.03],T3的平均差异为8.60 [CI为4.58 - 12.61,P < 0.0001])预后良好。
初始TSH升高(临床或亚临床甲状腺功能减退)可能对应更好的功能结局,而初始T3/fT3水平低可能与临床甲状腺功能正常的急性缺血性中风患者的更差结局相关。这种复杂关系值得进一步精心设计的研究。通过激素补充或拮抗来纠正甲状腺状况是否会导致更好的结局,将需要大型、前瞻性、干预性研究。